RxDoctor Payments Data

Long Tran

Physician Assistant · Banning, CANPI 1144403676

Payments from drug & device makers

$3,680in general payments, 2019–2025

Across 163 payments — averaging $22.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$1K
  • Novo Nordisk$642
  • Lilly USA, LLC$449
  • Amgen$274
  • Bayer$236
  • AbbVie$130
  • plus $809 from 16 others

What the payments were for

  • Food & beverage$3,680100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,680 in reported general payments places this provider in the 85th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide122$167,008
OzempicSemaglutide125$151,434
SynjardyEmpagliflozin/Metformin Hcl95$94,061
OtezlaApremilast12$60,898
JardianceEmpagliflozin50$57,806
Synjardy XrEmpagliflozin/Metformin Hcl48$53,574
MounjaroTirzepatide33$40,212
MyrbetriqMirabegron35$24,082
Trijardy XrEmpaglifloz/Linaglip/Metformin21$21,611
EliquisApixaban21$20,415
SeglurometErtugliflozin/Metformin29$16,996
XareltoRivaroxaban11$12,221
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$10,246
SteglatroErtugliflozin Pidolate13$8,286
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$8,065

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimSynjardy, Jardiance, Synjardy Xr, Trijardy Xr, Spiriva Respimat$1,140$235,078230 claims
Lilly USA, LLCTrulicity, Mounjaro$449$207,220155 claims
Novo NordiskOzempic$642$151,434125 claims
AmgenOtezla$274$60,89812 claims
MerckSegluromet, Steglatro$76$25,28242 claims
PfizerEliquis$97$20,41521 claims
Johnson & JohnsonXarelto$26$12,22111 claims
GSKTrelegy Ellipta$17$10,24614 claims
AstraZenecaBreztri Aerosphere$82$7,79411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Banning

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →